REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktails tested in fight against Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-stage study aims to find safe and effective doses of loncastuximab tesirine (an approved lymphoma drug) when combined with other anti-cancer drugs. It is for adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments. The main goal is t…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Apr 04, 2026 02:21 UTC
-
Scientists test 'One-Two Punch' of engineered immune cells and vaccine to fight tough lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and feasibility of a two-part treatment for aggressive B-cell lymphomas that have come back or are resistant to standard therapies. Doctors take a patient's own immune cells, engineer them in a lab to better target cancer, and then inf…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo targets Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new two-drug combination for people with advanced solid tumors, including pancreatic cancer, that have spread or stopped responding to standard treatments. The trial aims to find the best dose and see if the drugs can help c…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC